Loading
A tumour test that measures DNA-repair scarring so that women with ovarian cancer beyond BRCA carriers can benefit from PARP inhibitors.
Approved 23 October 2019 (PMA P190014) with niraparib for homologous-recombination-deficient ovarian cancer after several lines of therapy, and in May 2020 as the companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer (PAOLA-1). Roughly half of high-grade serous ovarian cancers are HRD-positive by this definition, about twice the BRCA-mutated fraction. The scar is permanent, so a tumour can remain HRD-positive after it has developed resistance, one reason the test predicts benefit better in first-line than in later lines.
Tumour BRCA1/2 sequencing combined with a genomic instability score (GIS) built from loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions; GIS ≥42 or a BRCA mutation defines HRD-positive. Connects to BRCA1 / BRCA2 (HRD) and PARP.
1.myChoice CDx slips into a pocket on BRCA1 / BRCA2 (HRD).
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Region | Year | Indication |
|---|---|---|
| US | 2019 | Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer |
| US | 2020 | Companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
The survival evidence behind platinum in early triple-negative disease, and the first large demonstration that most triple-negative tumours are DNA-repair deficient whether or not BRCA is mutated, which is why HRD scores have not become a platinum selection test.
This paper set the HRD score threshold the myChoice assay still uses and showed that genomic scars extend platinum sensitivity beyond BRCA carriers in early TNBC, though the TNT trial later found the same score did not predict carboplatin benefit in advanced disease.
Query for this drug: (TITLE:"myChoice CDx" OR ABSTRACT:"myChoice CDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about myChoice CDx, not a curated reading list.
Shares Myriad Genetics, HRD & BRCA testing, Companion diagnostics, PARP and the tag test.
Shares Myriad Genetics and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.
Shares Myriad Genetics and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.